Silence Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Silence Therapeutics has a total shareholder equity of £17.1M and total debt of £0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are £93.8M and £76.8M respectively.
Key information
0%
Debt to equity ratio
UK£0
Debt
Interest coverage ratio | n/a |
Cash | UK£54.03m |
Equity | UK£17.05m |
Total liabilities | UK£76.77m |
Total assets | UK£93.82m |
Recent financial health updates
Recent updates
Need To Know: Analysts Are Much More Bullish On Silence Therapeutics plc (NASDAQ:SLN) Revenues
Feb 07Subdued Growth No Barrier To Silence Therapeutics plc (NASDAQ:SLN) With Shares Advancing 65%
Nov 27Silence Therapeutics wins FDA’s fast track status for blood cancer therapy
Sep 08Silence Therapeutics prices 5.95M ADSs at $9.50/share
Aug 12New finance chief for Silence Therapeutics
Jan 06Financial Position Analysis
Short Term Liabilities: SLN's short term assets (£81.0M) exceed its short term liabilities (£17.8M).
Long Term Liabilities: SLN's short term assets (£81.0M) exceed its long term liabilities (£59.0M).
Debt to Equity History and Analysis
Debt Level: SLN is debt free.
Reducing Debt: SLN had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SLN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: SLN has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 27.1% each year.